Gut-liver axis in metabolic dysfunction-associated steatotic liver disease and steatohepatitis: Dysbiosis, metabolic mediators, and emerging microbiome-targeted therapies
World Journal of Hepatology · 20.11.2026
DOI: 10.4254/wjh.128445 ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Hepatology, online erschienen am 20.11.2026. Verfasst von Shamaela Mashneil und 5 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Mashneil, S., Salimi, H., Aung, Z. M., Elsayed, F., Malik, M., & Gupta, P. (2026). Gut-liver axis in metabolic dysfunction-associated steatotic liver disease and steatohepatitis: Dysbiosis, metabolic mediators, and emerging microbiome-targeted therapies. World Journal of Hepatology. https://doi.org/10.4254/wjh.128445
Vancouver
Mashneil S, Salimi H, Aung ZM, Elsayed F, Malik M, Gupta P. Gut-liver axis in metabolic dysfunction-associated steatotic liver disease and steatohepatitis: Dysbiosis, metabolic mediators, and emerging microbiome-targeted therapies. World Journal of Hepatology. 2026. doi:10.4254/wjh.128445
BibTeX
@article{Mashneil2026,
author = {Mashneil, Shamaela and Salimi, Hamna and Aung, Zaw Myo and Elsayed, Fatma and Malik, Mohammad and Gupta, Prakash},
title = {Gut-liver axis in metabolic dysfunction-associated steatotic liver disease and steatohepatitis: Dysbiosis, metabolic mediators, and emerging microbiome-targeted therapies},
journal = {World Journal of Hepatology},
year = {2026},
doi = {10.4254/wjh.128445}
}
EUVIMED